March 9, 2024

Just days ago, suc­cess in Eli Lil­ly’s 30-year pur­suit of an Alzheimer’s dis­ease drug seemed all but guar­an­teed. Now, the FDA’s eleventh-hour de­ci­sion to con­vene

The phar­ma in­dus­try got a glimpse Thurs­day night of what four more years of the Biden ad­min­is­tra­tion could look like. And they did not like

BeiGene cel­e­brat­ed its fifth in­di­ca­tion for Brukin­sa with a law­suit. A day af­ter win­ning an ac­cel­er­at­ed ap­proval in fol­lic­u­lar lym­phoma, BeiGene filed com­plaints against San­doz

John­son & John­son is once again the spon­sor of the health and medtech track at the SXSW Fes­ti­val, and it’s fea­tur­ing dis­ease sim­u­la­tions in pso­ri­at­ic

Akero Ther­a­peu­tics ex­pects its promis­ing ex­per­i­men­tal MASH drug will be used to treat pa­tients with ad­vanced fi­bro­sis if it re­ceives FDA ap­proval, liken­ing MASH to

The FDA on Fri­day ex­pand­ed the la­bel for No­vo Nordisk’s pop­u­lar weight loss in­jec­tion We­govy, ap­prov­ing it as a treat­ment to re­duce the risk of

Gilead Sci­ences is fo­cus­ing on the over­looked needs of peo­ple liv­ing with metasta­t­ic and triple-neg­a­tive breast can­cer in its lat­est un­brand­ed on­col­o­gy cam­paign. The “Ex­pose

Bar­ring safe­ty is­sues, the FDA al­most nev­er pulls ful­ly-ap­proved drugs from the mar­ket. But giv­en the mag­ni­tude of the fail­ure with Amy­lyx’s Phase III da­ta

Even if com­peti­tor man­u­fac­tur­ers at­tract the at­ten­tion of Catal­ent’s cus­tomers on the back of it be­ing ac­quired by No­vo Hold­ings, it will take time for